EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

Christof Vulsteke, Setsuko K Chambers, Maria Jesús Rubio Pérez, John K Chan, Nicoline Raaschou-Jensen, Ying Zhuo, Domenica Lorusso, Thomas J Herzog, Thibault de la Motte Rouge, Jessica A Thomes Pepin, Elena Ioana Braicu, Lee-May Chen und 8 weitere

European Journal of Cancer · 2024-09 · 208 · 114157

DOI: 10.1016/j.ejca.2024.114157 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024-09. Verfasst von Christof Vulsteke und 19 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Cancer Center, AZ Maria Middelares, Ghent, and Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium. Electronic ad…. Hauptthemen laut MEDLINE: Indazoles, Piperidines, Ovarian Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To explore safety and tolerability parameters for the niraparib individualized starting dose (ISD) in patients with newly diagnosed advanced ovarian cancer that responded to platinum-based chemotherapy who participated in the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial (NCT02655016). METHODS: The PRIMA protocol was amended so newly enrolled patients received an ISD based on baseline body weight/platelet count. In this ad hoc analysis, the timing, duration, and resolution of the first occurrence of common any-grade hematologic (thrombocytopenia, anemia, neutropenia) and nonhematologic (nausea, asthenia/fatigue, constipation, insomnia, hypertension) treatment-emergent adverse events (TEAEs) were evaluated by treatment arm in the ISD safety population (data cutoff, November 17, 2021; median follow-up, 3.5 years). RESULTS: Of 733 randomized patients, 255 were enrolled after the ISD protocol amendment and received ≥ 1 dose of study treatment (niraparib, 169; placebo, 86). In the niraparib arm, median times to first events were 22.0-35.0 days for hematologic TEAEs and 7.0-56.0 days for nonhematologic TEAEs. First events resolved in ≥ 89.8% of patients for hematologic TEAEs; for nonhematologic TEAEs, resolution rates ranged from 55.3% (insomnia) to 86.0% (nausea). Median durations of first hematologic TEAEs were ≤ 16.0 days, but for first nonhematologic TEAEs ranged from 18.0 days (nausea) to 134.0 days (insomnia). CONCLUSION: The niraparib ISD was generally well tolerated and TEAEs were manageable. Common hematologic and nonhematologic TEAEs occurred early and first events of hematologic TEAEs had a short duration (≈ 2 weeks) and a high resolution rate. These findings support close monitoring immediately following niraparib initiation and may help inform patient expectations for niraparib safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndazolesPiperidinesOvarian NeoplasmsHumansFemaleMiddle AgedAgedAdultPoly(ADP-ribose) Polymerase InhibitorsIsoquinolinesMaintenance Chemotherapy

Stichwörter der Autor:innen

Maintenance therapyNiraparibOvarian cancerPARP inhibitorTolerability

Substanzen

niraparibIndazolesPiperidinesPoly(ADP-ribose) Polymerase InhibitorsIsoquinolines

Autor:innen und Institutionen

  • Integrated Cancer Center, AZ Maria Middelares, Ghent, and Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium. Electronic address: christof.vulsteke@mijnziekenhuis.be.
  • University of Arizona Cancer Center, Tucson, AZ, USA.
  • Hospital Reina Sofía, Córdoba, and GEICO Grupo, Spain.
  • California Pacific Medical Center, Palo Alto Medical Foundation, Sutter Cancer Research Consortium, San Francisco, CA, USA.
  • Herlev Hospital Department of Oncology, Herlev, Denmark.
  • Kadlec Hematology and Oncology Clinic, Richland, WA, USA.

Förderung

  • GlaxoSmithKline Biologicals

Zitieren

APA

Vulsteke, C., Chambers, S. K., Pérez, M. J. R., Chan, J. K., Raaschou-Jensen, N., Zhuo, Y., Lorusso, D., Herzog, T. J., de la Motte Rouge, T., Thomes Pepin, J. A., Braicu, E. I., Chen, L. M., Levy, T., Barter, J. F., Pilar Barretina-Ginesta, M., Joosens, E., York, W., Malinowska, I. A., González-Martín, A., & Monk, B. J. (2024). Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy. European Journal of Cancer, 208, 114157. https://doi.org/10.1016/j.ejca.2024.114157

Vancouver

Vulsteke C, Chambers SK, Pérez MJR, Chan JK, Raaschou-Jensen N, Zhuo Y, et al. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy. European Journal of Cancer. 2024;208:114157. doi:10.1016/j.ejca.2024.114157

BibTeX
@article{Vulsteke2024,
  author = {Vulsteke, Christof and Chambers, Setsuko K and Pérez, Maria Jesús Rubio and Chan, John K and Raaschou-Jensen, Nicoline and Zhuo, Ying and Lorusso, Domenica and Herzog, Thomas J and de la Motte Rouge, Thibault and Thomes Pepin, Jessica A and Braicu, Elena Ioana and Chen, Lee-May and Levy, Tally and Barter, James F and Pilar Barretina-Ginesta, M and Joosens, Eric and York, Whitney and Malinowska, Izabela A and González-Martín, Antonio and Monk, Bradley J},
  title = {Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {208},
  pages = {114157},
  doi = {10.1016/j.ejca.2024.114157}
}
Kostenlos starten →